Updates are available Correction dated 2024-02-29
Click to view Correction: https://doi.org/10.1038/s41588-024-01693-y
-
Authors
Qin, Youwen http://orcid.org/0000-0003-3956-4711
Havulinna, Aki S. http://orcid.org/0000-0002-4787-8959
Liu, Yang
Jousilahti, Pekka
Ritchie, Scott C. http://orcid.org/0000-0002-8454-9548
Tokolyi, Alex http://orcid.org/0000-0003-4222-7484
Sanders, Jon G.
Valsta, Liisa
Brożyńska, Marta
Zhu, Qiyun
Tripathi, Anupriya
Vázquez-Baeza, Yoshiki http://orcid.org/0000-0001-6014-2009
Loomba, Rohit
Cheng, Susan http://orcid.org/0000-0002-4977-036X
Jain, Mohit
Niiranen, Teemu
Lahti, Leo http://orcid.org/0000-0001-5537-637X
Knight, Rob
Salomaa, Veikko http://orcid.org/0000-0001-7563-5324
Inouye, Michael http://orcid.org/0000-0001-9413-6520
Méric, Guillaume http://orcid.org/0000-0001-6288-9958
- License Information
-
More Information
Article History
Received: 21 October 2020
Accepted: 19 November 2021
First Online: 3 February 2022
Change Date: 29 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-024-01693-y
Competing interests
: V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also has ongoing research collaboration with Bayer AG, all unrelated to this study. R.L. serves as a consultant or advisory board member for Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Inipharm, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Promethera, Sanofi, Siemens and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus and Siemens. He is also cofounder of Liponexus, Inc. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
